The proof-of-principle study demonstrated the feasibility of altering the microbiome to elicit anti-PD-1 response and shed light on which patients might benefit.
Treating patients with their own lymphocytes has been tricky to define as a product from the commercial perspective, but a forthcoming approval may change that.
Based on the safety and anti-tumor activity seen among patients receiving Achilles' clonal neoantigen-targeting T cells, the trials will continue as planned.
The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.
